TITLE

Enteroviral Meningoencephalitis after Anti-CD20 (Rituximab) Treatment

AUTHOR(S)
Quartier, Pierre; Tournilhac, Olivier; Archimbaud, Christine; Lazaro, Leila; Chaleteix, Carine; Millet, Pascale; Peigue-Lafeuille, Hélène; Blanche, Stéphane; Fischer, Alain; Casanova, Jean-Laurent; Travade, Philippe; Tardieu, Marc
PUB. DATE
February 2003
SOURCE
Clinical Infectious Diseases;2/1/2003, Vol. 36 Issue 3, pe47
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Treatment with the chimeric anti-CD20 monoclonal antibody rituximab induces rapid and long-lasting depletion of circulating B cells. We report the occurrence of enteroviral meningoencephalitis following rituximab therapy in 1 child with immune thrombocytopenia and in 1 adult patient with relapsed B cell lymphoma.
ACCESSION #
9027459

 

Related Articles

  • Rituximab.  // Reactions Weekly;5/14/2011, Issue 1351, p38 

    The article describes the case of a 30-year-old man who developed late-onset neutropenia after receiving rituximab and radiotherapy for primary mediastinal B-cell lymphoma.

  • Treatment of B cell lymphoma with chemotherapy plus rituximab: a survival benefit can be demonstrated in the routine data of a regional cancer registry. Krause, Stefan; Gerken, Michael; Andreesen, Reinhard; Hofstädter, Ferdinand; Klinkhammer-Schalke, Monika // Annals of Hematology;Apr2012, Vol. 91 Issue 4, p561 

    Combination of standard chemotherapy with rituximab led to improved disease control in patients with B cell lymphoma in clinical trials. We wanted to know if a similar benefit could be demonstrated in the routine data of a regional population-based cancer registry. We searched the registry of...

  • Bendamustine/rituximab.  // Reactions Weekly;Feb2015, Vol. 1540 Issue 1, p60 

    The article presents a case study of five patients who developed various skin toxicities, including toxic dermatitis, erythema multiforme and chronic dermatitis, after receiving bendamustine and rituximab for the treatment of indolent B-cell lymphoma.

  • Epigenetics: Showing a more sensitive side. McCarthy, Nicola // Nature Reviews Cancer;Oct2013, Vol. 13 Issue 10, p680 

    The article presents a study of Ari Melnick and team that assesses the effectiveness of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) regimen in the treatment of diffuse large B cell lymphoma (DLBCL). They exposed patients' two lines of cell containing refractory...

  • Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ennishi, D.; Asai, H.; Maeda, Y.; Shinagawa, K.; Ikeda, K.; Yokoyama, M.; Terui, Y.; Takeuchi, K.; Yoshino, T.; Matsuo, K.; Hatake, K.; Tanimoto, M. // Annals of Oncology;Jun2010, Vol. 21 Issue 6, p1217 

    Background: A recent laboratory study indicated that statins impaired the antitumor effects of rituximab by inducing conformational changes in CD20. Although these findings raised significant concerns about statin use during rituximab treatment, their clinical significance is unclear.

  • Rituximab.  // Reactions Weekly;Jun2015, Vol. 1555 Issue 1, p174 

    The article presents case reports of five women who developed vulvovaginal pyoderma gangrenosum during therapy with rituximab for B-cell non Hodgkin's lymphoma.

  • Antineoplastics/doxorubicin.  // Reactions Weekly;Oct2015, Vol. 1575 Issue 1, p22 

    An abstract of the article "Upfront intensification incorporating dose-dense rituximab and high-dose MTX to chop-14 in young high-risk aggressive B-cell lymphoma patients," by T. Strusmann and colleagues is presented.

  • Enteroviral Encephalitis Leading to a Locked-in State. Elliott, Sean P.; Acharya, Victoria Z.; Talwar, Dinesh // Journal of Child Neurology;Nov2001, Vol. 16 Issue 11, p864 

    Millions of children are infected by enteroviruses each year, usually exhibiting only mild symptoms. Although enteroviruses are a common cause of community-acquired aseptic meningitis, enteroviral meningitis usually has a benign course. We describe a 14-year old patient with enteroviral...

  • Non-gastric marginal zone B cell lymphoma: clinicopathologic features and treatment results. Gill, Harinder; Chim, Chor-Sang; Au, Wing-Yan; Loong, Florence; Tse, Eric; Leung, Anskar; Kwong, Yok-Lam // Annals of Hematology;Dec2011, Vol. 90 Issue 12, p1399 

    The optimal treatment strategy and outcome of non-gastric marginal zone lymphoma (MZL) remains undefined. The role of rituximab and fludarabine in MZL has not been critically appraised and compared with conventional chemotherapy. We retrospectively analyzed 81 consecutive patients with...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics